THERAPY DOSSIER · th-a71be220119b

Sea buckthorn (Hippophae rhamnoides L.) berry polysaccharide extract (HRP), isolated by hot-water extraction

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26494508 ↗2015Reported benefit

Protective effects of sea buckthorn polysaccharide extracts against LPS/d-GalN-induced acute liver failure in mice via suppressing TLR4-NF-kappaB signaling.

MouseEndotoxin/LPSC57BL/6MaleOral50, 100 or 200 mg/kgPretreatment, given before the lipopolysaccharide/d-galactosamine challenge

Model: Acute liver failure induced by challenge with lipopolysaccharide 50 micrograms/kg plus d-galactosamine hydrochloride 300 mg/kg, with sacrifice 8 h after challenge

Pretreatment with the polysaccharide extract significantly inhibited the lipopolysaccharide/d-galactosamine induced rise in serum alanine aminotransferase and aspartate aminotransferase, alleviated histological liver injury and reduced tumour necrosis factor alpha, interleukin-1 beta and malondiald…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…